Capital International Sarl Has $1.55 Million Stock Position in Qiagen (NYSE:QGEN)

Capital International Sarl cut its position in Qiagen (NYSE:QGEN) by 10.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,292 shares of the company’s stock after selling 4,076 shares during the period. Capital International Sarl’s holdings in Qiagen were worth $1,553,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Riverview Trust Co acquired a new position in Qiagen during the first quarter worth $28,000. Tower Research Capital LLC TRC boosted its stake in Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock valued at $31,000 after acquiring an additional 283 shares during the last quarter. Park Place Capital Corp purchased a new position in Qiagen in the first quarter valued at approximately $36,000. Quarry LP purchased a new position in shares of Qiagen during the 4th quarter valued at $38,000. Finally, Lindbrook Capital LLC grew its stake in shares of Qiagen by 21.6% during the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after acquiring an additional 237 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on QGEN. JPMorgan Chase & Co. boosted their price objective on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. Stifel Nicolaus dropped their price target on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research note on Wednesday, May 1st. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a report on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.05.

Qiagen Price Performance

Shares of Qiagen stock traded up $1.68 during trading on Friday, hitting $43.92. The stock had a trading volume of 1,493,282 shares, compared to its average volume of 1,157,431. The firm has a market cap of $10.02 billion, a price-to-earnings ratio of 29.45, a P/E/G ratio of 3.25 and a beta of 0.40. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70. The business’s 50-day moving average is $42.59 and its 200 day moving average is $43.16. The company has a current ratio of 1.84, a quick ratio of 1.45 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 EPS. As a group, sell-side analysts anticipate that Qiagen will post 2.13 earnings per share for the current year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.